Palatin Technologies Inc (NYSE American:PTN)

0.9294
BATS BZX Real-Time Price
As of 10:22am ET
 -0.0015 / -0.16%
Today’s Change
0.59
Today|||52-Week Range
1.78
+31.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$225.2M

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Contact Information

Palatin Technologies, Inc.
Cedar Brook Corporate Center
Cranbury New Jersey 08512
P:(609) 495-2200
Investor Relations:

Employees

Shareholders

Individual stakeholders9.62%
Other institutional9.55%
Mutual fund holders10.98%

Top Executives

Carl SpanaPresident, Chief Executive Officer & Director
Stephen T. WillsCOO, CFO, Secretary, Treasurer & Executive VP
Johna LucasChief Medical Officer